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RadiotherapyAbstract Ewing’s sarcoma is typically an aggressive, poorly differentiated tumor affecting children
and young adults, it accounts for 4–6% of all primary bone tumors and facial primary localizations
occur in only 1–4% of all cases, mostly in the mandible and calvaria. Paranasal sinus involvement is
rare. A 22-year-old female was reviewed in Oral & Cranio Maxillofacial Surgery Department. She
complained of swelling of the right paranasal area, of one-month duration, progressively increasing
in size and associated with pain. The medical history was unremarkable, Contrast Enhanced
Computed Tomography scan showed a destructive lesion of the anterior wall of the right maxillary
sinus reaching up to the medial wall of the maxillary sinus, other paranasal sinus appearance was
normal. Incisional biopsy proved it to be Ewing’s Sarcoma. She was treated by chemotherapy using
Vincristine, Adriamycin, and Cyclophosphamide alternating with Etoposide & Ifosfamide and
Radiotherapy, and this resulted in complete regression of the tumor. Repeated PET scans every
6 months did not suggest any recurrence of the right maxillary sinus tumor. We concluded that
treatment by induction chemotherapy followed by radiation therapy leads to a favorable outcome
in the above described case, avoiding the morbidity that can result from surgical options.
ª 2015 Egyptian Society of Ear, Nose, Throat and Allied Sciences. Production and hosting by Elsevier
B.V. All rights reserved.1. Introduction
Ewing’s sarcoma is a malignant, small round cell tumor arising
from the bone. First described by James Ewing in 1921 this
tumor is of neuroectodermal origin, and it includes many sub-
sets, all of which are referred to as Ewing’s family of tumors
(EFT).Ewing’s sarcoma (ES) is typically an aggressive, poorly dif-
ferentiated tumor affecting children and young adults and is
rarely seen in older adults.1 The peak incidence in men is
between the ages of 10 and 14 years, whereas in women it is
between the ages of 5 and 9 years.2 White children have an
approximately nine fold higher incidence rate of ES than other
ethnicities.1 It accounts for 4–6% of all primary bone tumors3
and facial primary localizations occur in only 1–4% of all
cases, mostly in the mandible and calvaria. Paranasal sinus
involvement is rare, and skull base involvement has been infre-
quently reported.5
In the current article we are presenting our experience with
a case of maxillary sinus involvement. Clinical presentation,ed.
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discussed.
2. Case report
A 22-year-old female was referred to Oral & Cranio
Maxillofacial Surgery Department, in January 2011. She com-
plained of swelling of the right cheek ﬁrst noted one-month
ago. This swelling has been progressively increasing in size
and associated with pain.
The medical history was unremarkable, and the clinical
examination showed a 2 · 3 cm, ﬁrm right para nasal swelling,
extending to the infra orbital area. Nasal examination revealed
an enlarged inferior turbinate.
Contrast Enhanced Computed Tomography scan (CT) of
the face showed a destructive lesion of the anterior wall of
the right maxillary sinus reaching up to the medial wall of
the maxillary sinus, measures 32 · 34 · 33 mm in its maximal
anteroposterior, transverse, craniocaudal dimensions respec-
tively. Other paranasal sinuses appeared normal (Fig. 1).
Thinning out of the orbital ﬂoor is noted, with likely exten-
sion of the pathological lesion to the right orbit.
Subcentimetric bilateral submandibular and deep cervical
lymph node enlargements were noted as well.
An incisional biopsy was taken using the Functional
Endoscopic Sinus Surgery (FESS technique). The histological
ﬁndings showed a small round blue cell proliferation. The cells
were arranged in sheets and nests with clumped chromatin pat-
tern and scant cytoplasm. Focal cytoplasmic clearing was also
observed.
Given the differential of a small round blue cell tumor
including neuroendocrine carcinoma, rhabdomyosarcoma,
lymphoma etc, a panel of immunoperoxidase stains with
appropriates controls was performed. The neoplastic showed
strong staining with CD99 and Vimentin, additional stains
for epithelial differentiation (Cytokeratin), hematologic and
lymphoblastic markers (CD45 and TdT), rhabdoid differentia-
tion (Desmin) and neuroendocrine differentiation (NSE,Figure 1 Axial CT scan showing involvement of the anterior
wall of right maxillary sinus.chromogranin and Synaptophysin) were all negative. These
ﬁndings are consistent with those of Ewing’s sarcoma/PNET.
CT scan of the chest, abdomen and pelvis was done to
detect the presence of distant metastasis and the ﬁndings were
unremarkable, except for mild enlargement of the spleen.
Technetium-99 m bone scan did not show any evidence of dis-
tant metastatic deposits throughout the skeleton, and bone
marrow was free of any neoplastic process.
The case was discussed with the oncologist, and the deci-
sion was made to treat the patient by chemo radiotherapy.
The patient was started on systemic intravenous
chemotherapy treatment, with VAC alternating with IE proto-
col. The ﬁrst cycle of VAC was given on Feb 2011, which con-
sisted of: Vincristine 2 mg, Adriamycin 75 mg/m2, and
Cyclophosphamide 1200 mg/m2, all given on day one. This
was alternated with IE protocol (Etoposide & Ifosfamide).
In June 2011 (after chemotherapy and before radiother-
apy), MRI showed a decrease in the size of soft tissue intensity
lesion, measuring 17 · 17 · 15 mm in its anteroposterior,
transverse, craniocaudal dimensions respectively, denoting dis-
ease regression.
Radiotherapy was given for 6 weeks together with IE pro-
tocol starting from June 2011, about 3 months after the start
of chemotherapy, until August 2011.
In September 2011 (during the chemotherapy) CT scan
showed residual small soft tissue density abutting the anterior
wall of the right maxillary sinus measuring 10 · 10 mm with
associated mucosal thickening. The chemotherapy was then
continued, as before, with alternating protocols VAC and IE
until she had completed one year of treatment on February
2012.
Another CT scan after the completion of chemo radiother-
apy showed no change in the ﬁndings, which may represent
underlying ﬁbrosis rather than residual tumor, and this was
conﬁrmed with MRI that did not show any signiﬁcant mass
lesion (Fig 2)Figure 2 Axial CT scan showing ﬁbrosis after
chemoradiotherapy.
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2014, did not suggest any recurrence of the right maxillary
sinus tumor.
3. Discussion
The Ewing’s sarcoma family of tumors (EFT) includes ES of
bone (ESB), extra osseous ES (EES), peripheral primitive neu-
roectodermal tumor of bone (pPNET) and malignant small-
cell tumor of the thoracopulmonary region (Askin’s tumor),
all of which are neoplasms of neuroectodermal origin.1
Ewing’s Sarcoma of the facial bones is a rare pathological
entity and involvement of the maxilla is even rarer. A rapidly
enlarging, often painful mass is the most frequent clinical
presentation.6
Signs and symptoms may include paresthesia, loss of teeth,
and ulceration of the overlying mucosa. Tumor of the maxil-
lary sinus might not be detected until the lesion protrudes into
the nasal cavity and oral cavity, which can cause nasal obstruc-
tion, epistaxis, and destruction of the palate.7
In the case described in the current study, the patient pre-
sented with a ﬁrm mass on the right para nasal area with no
oral or nasal protrusion, and intact oral mucosa.
The CT scan is the radiographic study of choice. The most
common radiologic signs in osseous tissue sarcomas are expan-
sion and erosion of the cortical bones, with bone destruction,
with or without periosteal thickening. MRI, CT scan,
Technetium-99 m scintigraphy, and bone marrow samplings
are all diagnostic tools that can be used to detect the presence
of distant metastasis, as in this case that showed no
metastasis.2
According to the National Comprehensive Cancer Network
(NCCN) guidelines for bone cancer, deﬁnite diagnosis is based
on the histopathologic study of a biopsy, and this should be
achieved by means of core needle or surgical biopsy.2 In the
current study the incisional biopsy was taken using the
Functional Endoscopic Sinus Surgery (FESS technique).
Ewing’s sarcoma is one of the small, blue, round cell
tumors of childhood. Histologically, the main differential
diagnosis includes lymphoma, Rhabdomyosarcoma,
Neuroblastoma, Wilms and primitive Neuroectodermal tumor
(PNET).
In addition to histochemical analysis, molecular testing can
be helpful to identify signature translocations involving the
EWS gene (balanced translocation involving chromosomes
11 and 22). These translocations are detectable with both
reverse transcriptase polymerase chain reaction (RT-PCR)
and ﬂuorescence in situ hybridization (FISH) in formalin-
ﬁxed, parafﬁn-embedded tissue. RT-PCR had a sensitivity of
54% and speciﬁcity of 85%. This genetic anomaly can be rec-
ognized by the CD99 antibody. Although positive CD99 stain-
ing is highly sensitive for PNET/Ewing’s sarcoma, however,
not speciﬁc as many other tumors like lymphoblastic lym-
phoma may also express CD99.1
Diagnosis of PNET/Ewing’s sarcoma is made with tumors
showing typical morphologic features with supporting
immunoproﬁle and/or molecular ﬁndings. The morphologic
features include small round cell morphology with round
nucleus, scant cytoplasm with ﬁne chromatin with occasional
Homer-Wright or Flexner–Wintersteiner rosettes. The
immunoproﬁle includes reactivity with CD99 in the absenceof other markers of small round cell tumors with molecular
ﬁndings of translocations involving the EWS gene. In this case,
the tumor cells have small round cell morphology and were
strongly positive for CD99. This morphology is in conjunction
with the absence of other markers, including synaptophysin. S-
100, desmin, Cytokeratin, CD45, MyoD1, and TdT were con-
sistent with a diagnosis of PNET/Ewing’s Sarcoma.1
Before the development of effective chemotherapy, local
control measures alone were used for the treatment of localized
ES. A 5-year survival rate of 10–20% subclinical metastatic
disease is now assumed to be present in nearly all patients
because of the signiﬁcant relapse rate seen in patients who have
undergone local treatment without systemic chemotherapy.3
The use of adjuvant chemotherapy in EFT began in the early
1970s and has dramatically improved the overall survival1 with
5-year survival rates up to 70% in many large studies and a 10-
year survival of approximately 50%.3,4,8
In general, radical surgery is not provided as a primary
treatment modality. The current standard treatment of
Ewing’s sarcoma begins with chemotherapy unless otherwise
contraindicated. Even when the tumor appears resectable,
patients are submitted to 4–6 cycles of neoadjuvant
chemotherapy to eradicate micro metastatic disease and facil-
itate effective local control measures with wide negative
margins.2
In the current study the investigations did not show evi-
dence of metastatic disease at the time of presentation, and
as the surgical resection would include orbital exenteration
to achieve en bloc resection with negative margins, the decision
was to start chemotherapy followed by radiation therapy for
local control.
It is a signiﬁcant observation of note that debulking surgery
in Ewing’s sarcoma does not seem to offer any advantages in
terms of local control and its role appears to be limited to pal-
liative aims. Lymph node metastases from Ewing’s Sarcoma
are very rare. Considering this, it can be argued that elective
neck dissection is not indicated.2
Recurrence of Ewing’s sarcoma of the bone in general is
most common within 2 years of initial diagnosis (approxi-
mately 80%). The overall prognosis for patients with recurrent
Ewing’s sarcoma is poor.9,10
Ewing’s Sarcoma is an aggressive tumor that rarely affects
the facial skeleton. Treatment by induction chemotherapy fol-
lowed by radiation therapy leads to a favorable outcome in the
above described case, avoiding the morbidity that can result
from surgical options.Acknowledgment
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